---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-078622"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:14:19.802331+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics reports first LYTENAVA sales, $20.2M net loss for Q3 FY2025

## Summary
- First commercial sales of LYTENAVA (bevacizumab gamma) in Germany and UK; $1.5M revenue recognized.
- Net loss of $20.2M ($0.55 per share), compared to net loss of $0.89 per share in prior-year quarter.
- Adjusted net loss of $15.8M ($0.44 per share), excluding $2.3M change in promissory notes and $2.0M warrant liability.
- Cash and cash equivalents of $8.9M as of June 30, 2025.
- FDA PDUFA goal date for ONS-5010 (bevacizumab-vikg) set for August 27, 2025.

## SEC filing metadata
- accession: 0001104659-25-078622
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/0001104659-25-078622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-078622
- JSON: https://secwatch.observer/filing/0001104659-25-078622.json
- Plain text: https://secwatch.observer/filing/0001104659-25-078622.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.